LACEY PODY: Open Payments
NPI 1629581517 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,662 in 94 payments from 18 companies in 2025. Trend: 2023 $1,496 · 2024 $1,700 · 2025 $1,662
Food & beverage: $1,551Education: $111
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $238 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $200 |
| ABBVIE INC. | 23 | $198 |
| Teva Pharmaceuticals USA, Inc. | 9 | $192 |
| Supernus Pharmaceuticals, Inc. | 9 | $163 |
| Lundbeck LLC | 5 | $104 |
| Neurocrine BioSciences, Inc. | 4 | $89 |
| Corium, LLC | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $68 |
| Janssen Pharmaceuticals, Inc | 4 | $65 |
Products named: REXULTI, CAPLYTA, VRAYLAR, Qelbree, INGREZZA, Azstarys, TRINTELLIX, SPRAVATO.
Industry payments across AL — which companies pay providers there.
